BioSpace News Archive

The International Biomedical Research Alliance, a non-profit organization which provides programming and funding support for the National Institutes of Health (NIH) Oxford-Cambridge Scholars Program, today announced that Tom Heyman is joining the Alliance’s board of directors.

BioAscent Discovery Limited’s (www.bioascent.com) COO, Dr Sylviane Boucharens, has been included in the BioBeat 2018 list of 50 Movers and Shakers in BioBusiness

Alligator Bioscience today announces that it will receive payments of more than USD 3.5 million under its collaboration agreement with the South Korean company AbClon Inc.

Millar, Inc., OEM solutions partner for MEMS pressure sensors, is pleased to announce the company will be working with Indus Instruments, an innovator in preclinical research equipment, as a life sciences OEM customer

BioInvent International AB (OMXS: BINV), and Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies, announced they will be presenting two back-to-back posters featuring positive data supporting their ongoing collaboration to develop a novel oncolytic virus encoding for an anti-CTLA-4 antibody at the annual meeting of the Society for Immunotherapy of Cancer (SITC) to be held November 7-11 in Washington, D.C.

Oncodesign (Paris:ALONC) (ALONC – FR0011766229), a biopharmaceutical group specialized in precision medicine, is announcing a service partnership with Galderma, a dermatological unit belonging to Nestlé Skin Health.

TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy On Track

Verastem, Inc. today announced a collaboration with The Leukemia & Lymphoma Society® (LLS), to accelerate the development of duvelisib for the treatment of patients with peripheral T-cell lymphoma

Positive safety and efficacy trends of AR-301 in Phase 1/2a clinical trial was presented at the 31st Annual Congress of the European Society of Intensive Care Medicine

Both RELEASE-1 and RELEASE-2 Studies Demonstrated Highly Statistically Significant Results (P=0.006 and P=0.002 respectively) on Efficacy Endpoints